Synaptogenix Inc (SNPX)

[SF Wolf]

doingmybest you asked: “would you not view this as a take it all or nothing type of approach? Tackling the upper end of patients suffering is so much of a stretch given the current level of research on this drug and on success to date by other companies with this disease state that is strikes me as quite extraordinary. Is it just a home run shot by a newcomer taking a low probability attempt at a huge product, or, is it more completely reflective of their high degree of confidence based on all their sound work, which they view as a high probability of success, though without human data just yet.”

I have stated on this board that I believe NTRP telegraphed their expectations for their upcoming P2b results at the recent BIO CEO and Noble Conferences. In the end there was no equivocation, no doubts, that they expect success in their Ph2b trial. I think any reasonable person listening to both recordings would come to the same conclusions.

You wrote in another post, “I can attest to the excitement level working in a BP company a decade ago when there was a whisper of promise from the lab or the clinic due to the AD space being so coveted today in pharma.”

Looking over Nuerotope’s Power Point presentation from October 2016 I noticed on Page 16 that it states “First patients dosed January 2016”.

What that tells us is that an unknown number of advanced AD patients have already completed their Bryostatin or placebo treatments. Have the researchers at NTRP not already seen some of the human data, the raw data, even if it was still blinded? Probably.

I think that your poetic “whisper of promise” has excited the folks over at Nuerotrope.

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Neurotrope_BioScience_files/Neurotrope%20%20100516.pdf